Qube Research & Technologies (QRT)’s Dyne Therapeutics DYN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.59M	Sell	253,153 -159,287	-39%	-$2.75M	0.01%	1706
2025 Q4	$8.07M	Sell	412,440 -417,329	-50%	-$7.9M	0.01%	1480
2025 Q3	$10.5M	Buy	829,769 +37,782	+5%	+$431K	0.01%	1295
2025 Q2	$7.54M	Buy	791,987 +111,151	+16%	+$1.22M	0.01%	1466
2025 Q1	$7.12M	Buy	680,836 +413,459	+155%	+$5.91M	0.01%	1339
2024 Q4	$6.3M	Buy	267,377 +244,211	+1,054%	+$7.22M	0.01%	1362
2024 Q3	$832K	Buy	+23,166	New	+$922K	﹤0.01%	2096
2024 Q2	–	Sell	-100,656	Closed	-$2.86M	–	4019
2024 Q1	$2.86M	Buy	100,656 +47,312	+89%	+$1.07M	﹤0.01%	1558
2023 Q4	$709K	Buy	+53,344	New	+$521K	﹤0.01%	2104
2023 Q2	–	Sell	-17,726	Closed	-$204K	–	2538
2023 Q1	$204K	Buy	+17,726	New	+$230K	﹤0.01%	1933

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Qube Research & Technologies (QRT)'s DYN Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Dyne Therapeutics (DYN) stake by 39% in Q1 2026, selling an estimated $2.75M and leaving 253,153 shares worth $4.59M. The position accounts for 0.01% of the portfolio, ranked #1706.

Qube Research & Technologies (QRT) first reported a position in DYN in Q1 2023 and has held it in 10 quarters since. The position peaked at $10.5M in Q3 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Qube Research & Technologies (QRT) held 253,153 shares of Dyne Therapeutics worth $4.59M as of Q1 2026.
Qube Research & Technologies (QRT) sold 159,287 Dyne Therapeutics shares in Q1 2026, an estimated $2.75M.
Dyne Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #1706 holding.
Qube Research & Technologies (QRT) first reported a position in Dyne Therapeutics in Q1 2023 and has held it in 10 quarters since.
Qube Research & Technologies (QRT)'s Dyne Therapeutics position peaked at $10.5M in Q3 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.